Compare Stocks

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.55 +2.0%	$0.00	$1.07 ▼ $5.26	$90.37M	0.85	16,124 shs	31,015 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.0893 of 5 stars	3.5	3.0	0.0	0.0	1.9	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$7.00	174.51% Upside

Current Analyst Ratings

Latest ARMP, BOT, and RAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$4.53M	20.35	N/A	N/A	($0.89) per share	-2.87

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$69.04M	-$1.98	N/A	N/A	N/A	-1,524.51%	-280.95%	-52.61%	5/9/2024 (Estimated)

Latest ARMP, BOT, and RAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	ARMP Armata Pharmaceuticals	N/A	-$0.55	-$0.55	-$0.55	$0.68 million	$1.53 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	1.16	1.16

Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	85.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	66	36.15 million	5.24 million	Not Optionable

ARMP, BOT, and RAC Headlines

Source	Headline
	Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update americanbankingnews.com - April 16 at 5:58 AM
	Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8% marketbeat.com - April 13 at 12:40 AM
	Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development markets.businessinsider.com - March 25 at 9:35 PM
	Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses finance.yahoo.com - March 23 at 6:02 AM
	Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth markets.businessinsider.com - March 22 at 6:26 PM
	Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC Wainwright marketbeat.com - March 22 at 11:45 AM
	Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update finanznachrichten.de - March 22 at 8:33 AM
	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update finance.yahoo.com - March 21 at 5:31 PM
	INVA Apr 2024 15.000 call finance.yahoo.com - March 15 at 9:13 PM
	INVA Mar 2024 7.500 call finance.yahoo.com - March 10 at 5:07 PM
	Armata secures $35 million to fund phage therapy trials investing.com - March 6 at 4:20 PM
	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva finance.yahoo.com - March 4 at 4:17 PM
	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit finance.yahoo.com - February 21 at 8:42 AM
	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit prnewswire.com - February 21 at 7:00 AM
	Armata Pharmaceuticals Inc (ARMP) investing.com - February 10 at 5:30 PM
	Armata Pharmaceuticals Inc ARMP morningstar.com - February 2 at 10:01 PM
	Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy Rating markets.businessinsider.com - November 15 at 11:46 PM
	Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates finance.yahoo.com - November 15 at 1:46 PM
	Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update finanznachrichten.de - November 15 at 8:45 AM
	Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update finance.yahoo.com - November 14 at 7:41 PM
	Lexeo Therapeutics Inc. money.usnews.com - November 6 at 10:49 PM
	Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference finance.yahoo.com - October 30 at 9:28 AM
	Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 finance.yahoo.com - October 19 at 8:55 AM
	Armata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16 msn.com - October 4 at 10:01 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
PayPal Appears to Have Bottomed, is it Time to Buy?
March 22, 2024 9:11 AM
View PayPal Appears to Have Bottomed, is it Time to Buy?
Nike Stock and the 30% Rally That's Expected
March 22, 2024 9:45 AM
View Nike Stock and the 30% Rally That's Expected
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
March 28, 2024 9:25 AM
View Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Intuitive Machines: Charting a Course Among the Stars
March 21, 2024 11:30 AM
View Intuitive Machines: Charting a Course Among the Stars

All Headlines

Company Descriptions

Armata Pharmaceuticals

NYSEAMERICAN:ARMP

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial